Truist Financial Corp Sells 21,444 Shares of Haleon PLC Sponsored ADR $HLN

Truist Financial Corp reduced its position in shares of Haleon PLC Sponsored ADR (NYSE:HLN) by 4.1% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 495,921 shares of the company’s stock after selling 21,444 shares during the quarter. Truist Financial Corp’s holdings in Haleon were worth $5,143,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Allspring Global Investments Holdings LLC lifted its position in shares of Haleon by 6.1% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 30,223 shares of the company’s stock valued at $306,000 after buying an additional 1,749 shares in the last quarter. Acadian Asset Management LLC purchased a new position in shares of Haleon during the 1st quarter valued at about $1,767,000. Arlington Partners LLC purchased a new position in shares of Haleon during the 2nd quarter valued at about $2,315,000. Oppenheimer & Co. Inc. lifted its position in shares of Haleon by 11.2% during the 1st quarter. Oppenheimer & Co. Inc. now owns 25,362 shares of the company’s stock valued at $261,000 after buying an additional 2,564 shares in the last quarter. Finally, Concurrent Investment Advisors LLC lifted its position in shares of Haleon by 32.9% during the 1st quarter. Concurrent Investment Advisors LLC now owns 16,363 shares of the company’s stock valued at $168,000 after buying an additional 4,055 shares in the last quarter. 6.67% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

HLN has been the topic of a number of analyst reports. Barclays cut Haleon from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, September 16th. Weiss Ratings reissued a “hold (c)” rating on shares of Haleon in a report on Saturday, September 27th. The Goldman Sachs Group raised Haleon from a “neutral” rating to a “buy” rating in a report on Wednesday, September 10th. Finally, Wall Street Zen cut Haleon from a “buy” rating to a “hold” rating in a report on Saturday, July 12th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $12.33.

Haleon Stock Up 0.3%

Shares of HLN opened at $8.82 on Wednesday. The stock has a market capitalization of $39.28 billion, a price-to-earnings ratio of 22.60, a price-to-earnings-growth ratio of 2.60 and a beta of 0.20. Haleon PLC Sponsored ADR has a 1 year low of $8.71 and a 1 year high of $11.42. The business’s 50 day simple moving average is $9.46 and its 200-day simple moving average is $10.05. The company has a debt-to-equity ratio of 0.48, a current ratio of 0.87 and a quick ratio of 0.63.

Haleon Increases Dividend

The company also recently disclosed a semi-annual dividend, which was paid on Thursday, September 18th. Stockholders of record on Friday, August 15th were issued a dividend of $0.0555 per share. This is a positive change from Haleon’s previous semi-annual dividend of $0.05. The ex-dividend date of this dividend was Friday, August 15th. This represents a dividend yield of 190.0%. Haleon’s payout ratio is currently 28.21%.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.